Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

NCT02806648 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT02806648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02806648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
January 31, 2018
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine cancer